Evidence map›Paper›PMID 41323768›Full record

ArticleAmerican journal of ophthalmology case reports2025

Clinical utility of pembrolizumab in the management of orbital recurrence of uveal melanoma: case report.

Diego Strianese, Maria Paola Laezza, Maria Laura Passaro, Andrea Elefante, Antonella D'Aponte, Claudio Barbato, Luigi Formisano, Adriana Iuliano, Ciro Costagliola, Francesco Matarazzo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Diego StrianeseDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Maria Paola LaezzaDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Maria Laura PassaroDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Andrea ElefanteDepartment of Biomedical Science, University of Naples "Federico II" School of Medicine, Italy.
Antonella D'AponteDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Claudio BarbatoDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Luigi FormisanoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80131, Naples, Italy.
Adriana IulianoDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Ciro CostagliolaDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.
Francesco MatarazzoDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Orbital recurrence from uveal melanomas occurs in 3-23 % of enucleated eyes and poses a management challenge. Treatment options are disfiguring, and many tumors will progress despite management with surgery and radiation. Case report: This case explores the use of pembrolizumab to an orbital recurrence of uveal melanoma. A 80-year-old man developed recurrent orbital disease 11 years after enucleation for uveal melanoma and refused exenteration. As alternate management option he received 200 mg every three weeks of pembrolizumab. The orbital recurrence was reduced in size by 60 % in dimension as measured by MRI and CT imaging. After 20 months of treatment, the patient experienced deterioration of the dementia and spontaneously discontinued the therapy. Conclusion: This case demonstrates that pembrolizumab therapy can result in tumor regression of recurrent orbital uveal melanoma and it eventually may be helpful as a neoadjuvant treatment.

Indexed as

Choroidal melanomaDormancyEnucleationImmunotherapyOrbital recurrencePembrolizumab

Identifiers

PMID41323768
PMCPMC12664425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.